Research
Hormonal
Fecal microbiota transplantation (FMT) from lean donors improves peripheral and hepatic insulin sensitivity in patients with metabolic syndrome.
For some patients with metabolic syndrome, transferring healthy gut bacteria from lean donors via FMT can improve how their body uses insulin. This is a medical procedure, not a DIY fix, and is currently an area of active research for treating metabolic disorders.
ModerateSupportsMEDIUM confidence
Patients with metabolic syndrome who received small intestinal infusions of fecal microbiota from allogenic lean donors for 6 wk showed an improvement in peripheral and hepatic insulin sensitivity, along with an increase in butyrate-producing intestinal microbiota.
Why this rating
Based on a single report mentioned in the review; requires further validation.
Source
Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective
Jun-Ling Han et al. · World Journal of Gastroenterology · 2014
DOI 10.3748/wjg.v20.i47.17737
narrative_reviewCited 178×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Modulating gut microbiota using probiotics, prebiotics, antibiotics, or fecal microbiota transplantation improves glucose metabolism and insulin resistance in type 2 diabetes.Moderate
- Antibiotic treatment (specifically norfloxacin and ampicillin) improves fasting blood glucose and oral glucose tolerance in obese, insulin-resistant mice by reducing plasma LPS levels and intestinal inflammation.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →